Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: HIV (EU5)

Product Code:
Publication Date:
April 2016

Can prescription barriers help the 2nd and 3rd place HIV brands catch up to the runaway market leader?

In the European HIV treatment market, the leading brand is comfortably ahead—but can market barriers help either of the 3rd-place contenders move up to the #2 spot.

Market Access Impact: HIV shows you which brands you’re losing share to, which brands you’re taking it from, and why.

Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Celsentri, Evotaz, Intelence, Isentress, Stribild, Triumeq, Truvada, and Viread.

You’ll find out which brands your brand is losing share to, which ones you’re taking it from, and why—information you can use to compete more effectively.

Not your market? Click here to see the US report 

Request Sample Pages

Get Answers to Key Questions about HIV Drug Brands

  • Celsentri (maraviroc; ViiV Healthcare): Which two leading FDCs does Celsentri take the most share from?
  • Evotaz (atazanavir/cobicistat; BMS): Which barrier do more than twice as many doctors experience with Evotaz than any other brand?
  • Intelence (etravirine; Janssen Therapeutics): Is limited availability or patient preference a bigger issue for doctors prescribing Intelence?
  • Isentress (raltegravir; Merck & Co.): Isentress and Stribild are prescribed equally. Which brand has better awareness among doctors?
  • Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead): Which market barrier costs Stribild more than twice as much share as any other?
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare): Nearly half of Triumeq’s share loss is to one other brand. Which one?
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead): Which barrier is responsible for over a third of Truvada’s net share gain?
  • Viread (tenofovir disoproxil fumarate; Gilead): Viread sees a net share gain from all but two surveyed brands. Which two?

Top Takeaways

  • Clear winners and losers: The two most prescribed brands have the biggest market share and barrier-related gains, while the two least prescribed brands have the smallest share and the greatest losses.
  • Half of brands benefit from barriers: But the two biggest winners see significantly bigger gains than the other two brands.
  • Brand awareness is high: With one exception, at least 97% of doctors surveyed are aware of any given brand.
  • Barrier effect is uneven: The number of doctors who experience the top 2 market barriers varies greatly from brand to brand.
  • No clear advantage for FDCs vs. monotherapies: Of the four most prescribed brands, two are fixed-dose products while the other two are monotherapies.
  • Cost and labelling issues have the greatest impact: Barriers related to guidelines and patient type restrictions affect more prescriptions than any others.
  • Barrier effect significant for “other” brands: Taken together, “other” brands have a greater market share than 3/4 of the surveyed brands, and see the third biggest net gain due to barriers.

Exploring Market Access Issues

Market Access Impact: HIV explores key issues affecting HIV drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest effect?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge


We surveyed 150 infectious disease specialists — 30 from each EU5 country (France, Italy, Germany, Spain, UK) — chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between March 2nd and 9th, 2016.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved